FDA Approves Olaparib for mCRPC SubsetMay 20th 2020
The FDA has approved olaparib (Lynparza) for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide (Xtandi) or abiraterone acetate (Zytiga).
Olaparib Boosts Survival in Prostate Cancer SubsetApril 26th 2020
Olaparib (Lynparza) significantly improved overall survival (OS) versus abiraterone acetate (Zytiga) or enzalutamide (Xtandi) in patients with metastatic castration-resistant prostate cancer (mCRPC) harboring BRCA1/2 or ATM mutations, which are subsets of homologous recombination repair (HRR) gene mutations, according to updated findings from the phase III PROfound trial.
NDA Submitted for Single-Agent Relugolix to Treat Prostate CancerApril 21st 2020
A New Drug Application (NDA) has been submitted to the FDA for single-agent relugolix for use as a treatment for men with advanced prostate cancer, according to Myovant Sciences, the developer of the oral GnRH receptor antagonist.
PARP Inhibitors Continue to Show Promise in Prostate Cancer TreatmentMarch 31st 2020
The use of PARP inhibitors against DNA damage repair (DDR) alterations in prostate cancer is the first display of the potential for widespread precision medicine in the field, according to William K. Oh, MD, in a presentation during the 13th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies.
Rapid Sequencing in mCRPC May Alleviate ChallengesMarch 23rd 2020
The optimal sequencing of therapies for patients with metastatic castration-resistant prostate cancer (mCRPC) has proven to be a significant clinical challenge following the approvals of additional agents, said William K. Oh, MD.
Localized Bladder Cancer Treatment Continues to Change: Expert Weighs InMarch 21st 2020
Treatment options for patients with localized bladder cancer, beyond Bacillus Calmette-Guérin (BCG), are evolving as immunotherapies and novel agents are gaining traction in the management of this population, according to John P. Sfakianos, MD.
Antidepressant May Improve Prostate Cancer OutcomesMarch 4th 2020
The antidepressant phenelzine showed antitumor activity in patients with biochemical recurrent castrate-sensitive prostate cancer, according to a pilot study conducted by researchers at the University of Southern California (USC).
Ilixadencel Added to Sunitinib May Improve RCC OutcomesFebruary 15th 2020
The addition of the off-the-shelf cancer immune primer ilixadencel to sunitinib (Sutent) trended toward a benefit in overall survival (OS) compared with sunitinib alone as a first-line treatment for patients with newly diagnosed metastatic renal cell carcinoma (RCC).
Increasing Prostate Cancer Screening Takes a Team ApproachFebruary 6th 2020
With the advent of targeted therapy, understanding the genetic components of a patient's disease has become critical in oncology. As the role of genetic testing in prostate cancer has grown, the field is also overcoming hurdles with making it more widespread, said Thomas J. Polascik, MD.
Immunotherapy Combos Are Now Standard of Care for Advanced RCCJanuary 13th 2020
The standard of care for treatment-naïve patients with advanced renal cell carcinoma (RCC) has shifted from a single-agent VEGF TKI to a checkpoint inhibitor plus either a VEGF TKI or a CTLA-4 inhibitor, explained David F. McDermott, MD.
Next-Generation Imaging Will Change Prostate Cancer ParadigmJanuary 11th 2020
Novel next-generation imaging modalities have greater visibility than conventional imaging tools, leading to higher detection rates and earlier treatment of early recurrences and metastatic disease among men with prostate cancer, explained Hussein Aoun, MD.
FDA Approves Pembrolizumab for BCG-Unresponsive, High-Risk Bladder CancerJanuary 9th 2020
The FDA approved pembrolizumab (Keytruda) for the treatment of patients who are unresponsive to Bacillus Calmette-Guerin (BCG) treatment with high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.
New Agents Are Revamping Prostate Cancer TreatmentDecember 20th 2019
Three pivotal trials demonstrating improved metastasis-free survival (MFS) with 3 different oral antiandrogen agents in combination with androgen deprivation therapy (ADT) have led to FDA approvals that have transformed the treatment paradigm in nonmetastatic castration-resistant prostate cancer (CRPC), said Elisabeth I. Heath, MD, FACP.
Immunotherapy Brings More Options for Frontline RCC TreatmentDecember 18th 2019
Within approximately 1 year, 3 combination regimens featuring immunotherapy agents were approved by the FDA for the frontline treatment of patients with metastatic renal cell carcinoma (RCC), said Robert J. Motzer, MD.
FDA Grants Pembrolizumab Priority Review for High-Risk Bladder CancerDecember 2nd 2019
The FDA has granted a priority review designation to pembrolizumab (Keytruda) for the treatment of patients with Bacillus Calmette-Guerin (BCG)–unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in-situ (CIS) with or without papillary tumors who are ineligible for or chose to not undergo cystectomy.
Phase III CARD Trial Shows Promise For Combining Novel Treatment With Chemo In Advanced Prostate CancerOctober 25th 2019
Results from the phase III CARD trial suggest positive outcomes for patients with advanced prostate cancer on a novel treatment chemotherapy combination therapy treatment.